Diana Mckenzie - May 1, 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
May 1, 2024
Transactions value $
$0
Form type
4
Date filed
5/3/2024, 04:18 PM
Previous filing
Apr 3, 2024
Next filing
May 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +1K +38.46% $0.00 3.6K May 1, 2024 Direct F1
transaction VRTX Common Stock Disposed to Issuer -1.17K -32.41% 2.44K May 1, 2024 Direct F2
holding VRTX Common Stock 207 May 1, 2024 Held in Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Deferred Stock Units Award +1.17K +24.22% 5.99K May 1, 2024 Common Stock 1.17K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2 Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2023, Ms. McKenzie deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units.
F3 Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.